European Archives - Page 881 of 1107 - European Medical Journal

Novel Immunotherapy Agents for Acute Lymphoblastic Leukaemia

Acute lymphoblastic leukaemia (ALL) in adults has a survival rate of 40–50% at 5 years, with a high relapse rate after first-line chemotherapy.

A Theoretical View of Ovarian Cancer Relapse

Ovarian cancer (OC) is a disease that almost invariably relapses even after optimal primary cytoreductive surgery and standard first-line platinum-based…

Philips supports global transformation of pathology with two new fully digitized labs in Austria

Amsterdam, 29 August, 2017 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the continued momentum of…

Study Results: Titanium-Nitride-Oxide (TiNO) Coated Stent Is Non-Inferior to Bioabsorbable Polymer Everolimus-Eluting Stent (EES), for Patients Presenting with Acute Coronary Syndrome (ACS)

Barcelona, 29 August, 2017 – During the Late Breaking Science session at the European Society of Cardiology (ESC) Congress in Barcelona, Dr. Pim Tonino…

EMJ

EULAR 2017 – Interview – Dr João Fonseca

An interview with Dr João Fonseca (Lisbon Academic Medical Centre, Portugal) at this year’s EULAR congress held in Madrid, Spain.

EHA – 2017 – Congress Highlights

Grab our full congress review of EHA 2017 in EMJ’s Hematology 5.1 eJournal. In the meantime take a look at this year’s congress highlights.

EMJ

EHA 2017 – Opening Ceremony

Our full congress review of EHA 2017 is now available for free in our Hematology 5.1 eJournal, and here is a look at the opening ceremony.

EAACI 2017 – Interview – Prof Maria Jose Torres

An interview with Prof Maria Jose Torres (Malaga Regional University Hospital, Spain) at this year’s EAACI congress held in Helsinki, Finland.

EAACI 2017 – Interview – Dr Enrico Heffler

An interview with Dr Enrico Heffler (Humanitas University, Italy) at this year’s EAACI congress held in Helsinki, Finland.

The Potential of Immune Cells to Treat Allergy and Infection

SUCCESSFUL allergy and infection therapies may be possible following recent insights into the development and function of newly discovered Type 1…